Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Committee Wants Compulsory Licensing To Secure Cheap COVID-19 Products

ABPI Says Suggestion Is ‘Disappointing’

Executive Summary

Some way needs to be found to guarantee the supply of coronavirus products as more of them begin to become available, but the pharmaceutical industry says compulsory licensing is not the answer.

You may also be interested in...

‘Onshoring’ Not The Way To Tackle UK Coronavirus-Related Demand

A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.

EFPIA Rejects EU Calls To Relax IP Protections

State-imposed mechanisms such as compulsory licensing will discourage rather than encourage investment in R&D, says Europe’s research-based industry. It has also dismissed suggestions that Europe is too dependent on API supplies from third countries.

Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month

France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts